N. Colombo

发表

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.

A. Isacchi, E. Casale, C. Mercurio, 2010, Journal of medicinal chemistry.

Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer

S. Minucci, U. Cavallaro, N. Colombo, 2018, Cell Death & Differentiation.

Cervical re-injection of indocyanine green to improve sentinel lymph node detection in endometrial cancer.

A. Mariani, N. Colombo, F. Multinu, 2021, Gynecologic oncology.

Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months

Massimo Bellomi, Daniela Origgi, Francesca Botta, 2018, European Radiology.

Epigenome-based cancer risk prediction: rationale, opportunities and challenges

Andrew E. Teschendorff, Yvonne Vergouwe, Yann Joly, 2018, Nature Reviews Clinical Oncology.

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

V. Torri, C. Belloni, M. Valsecchi, 1990, British Journal of Cancer.

A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer

D. Cacchiarelli, J. Walter, G. Pruneri, 2020, Genome medicine.

A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer

D. Cacchiarelli, J. Walter, G. Pruneri, 2018, Genome Medicine.

Follow-up in Gynecological Malignancies: A State of Art

R. Kimmig, P. Zola, T. Maggino, 2015, International Journal of Gynecologic Cancer.

Optimal treatment of early-stage ovarian cancer

J. Ledermann, A. Lissoni, N. Colombo, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

What have we learned from ICON1 and ACTION?

N. Colombo, S. Pecorelli, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

What have we learned from ICON1 and ACTION?

N. Colombo, S. Pecorelli, 2003, International Journal of Gynecologic Cancer.

Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors.

D. Radice, N. Colombo, V. Zanagnolo, 2016, American journal of obstetrics and gynecology.

Imaging in gynecological disease (8): ultrasound characteristics of recurrent borderline ovarian tumors

D. Timmerman, L. Valentin, N. Colombo, 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Sentinel node biopsy in early vulvar cancer

N. Colombo, M. Cremonesi, A. Maggioni, 2000, British Journal of Cancer.

The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO).

M. Burnell, P. Zola, N. Colombo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Ovarian cancer: screening, treatment, and followup.

Robert C. Bast, Robert W. Makuch, Alice S. Whittemore, 1995, NIH consensus statement.

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

J. Berek, P. Sabbatini, T. Pintér, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

V. Torri, M. Parmar, J. Ledermann, 2003, The Lancet.

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

A. Oza, I. Bondarenko, N. Colombo, 2022, The Lancet. Oncology.

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).

J. Sehouli, F. Cognetti, N. Colombo, 2013, Gynecologic oncology.

Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.

M. Gore, N. Colombo, 2007, Critical reviews in oncology/hematology.

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.

A. Tinker, A. Oza, J. Ledermann, 2021, JAMA oncology.

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

M. Gobbi, N. Colombo, M. Miglino, 2015, Leukemia research.

Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression

A. Ibatici, N. Colombo, A. Signori, 2013, British journal of haematology.

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

B. Monk, I. Vergote, S. Pignata, 2019, Gynecologic oncology.

De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”

M. Gobbi, N. Colombo, M. Miglino, 2013, Annals of Hematology.

DNA methylation signatures to predict the cervicovaginal microbiome status

M. Widschwendter, M. Zikan, J. Timms, 2020, Clinical epigenetics.

Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.

P. Ruff, N. Colombo, G. Scambia, 2020, Gynecologic oncology.

Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study

A. Oza, A. Cardona, N. Colombo, 2018, International Journal of Gynecologic Cancer.

Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.

S. Pignata, N. Colombo, G. Scambia, 2016, Critical reviews in oncology/hematology.

Diaphragmatic Surgery During Primary Cytoreduction for Advanced Ovarian Cancer: Peritoneal Stripping Versus Diaphragmatic Resection

F. Landoni, N. Colombo, I. Zapardiel, 2011, International Journal of Gynecologic Cancer.

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

F. Landoni, C. Sessa, N. Colombo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

K. Robison, A. Okamoto, L. Molinero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors

A. Oza, G. Finocchiaro, N. Colombo, 2021, The oncologist.

Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy

P. Allavena, A. Mantovani, M. D’Incalci, 1989, International journal of cancer.

Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)

A. Isacchi, E. Felder, M. Ciomei, 2014 .

Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

A. Isacchi, E. Felder, M. Ciomei, 2018, Experimental and Molecular Therapeutics.

Outcome according to residual disease (surgeon's report vs pre‐chemotherapy imaging) in patients with bevacizumab‐treated ovarian cancer: Analysis of the ROSiA study

A. Oza, N. Colombo, F. Selle, 2019, Journal of surgical oncology.

The obese endometrial cancer patient : how dowe effectively improve morbidity and mortality in this patient population ?

A. Leary, N. Colombo, P. Morice, 2016 .

Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy

F. Fazio, N. Colombo, S. Pecorelli, 2000, British Journal of Cancer.

Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

A. Reuss, H. Mackay, A. Oza, 2010, International Journal of Gynecologic Cancer.

Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study.

S. Rizzo, M. Bellomi, N. Colombo, 2019, European journal of radiology.

Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.

A. Isacchi, G. Canevari, E. Felder, 2015, Bioorganic & medicinal chemistry.

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

N. Colombo, Genny Del Zotto, S. Candiani, 2021, Frontiers in Immunology.

Tumor progression and metastatic dissemination in ovarian cancer after dose‐dense or conventional paclitaxel and cisplatin plus bevacizumab

M. Zucchetti, P. Ubezio, E. Erba, 2018, International journal of cancer.

The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium.

A. Godwin, P. Nuciforo, M. Herlyn, 2008, Cancer research.

SENTINEL NODE DETECTION IN CERVICAL CANCER

F. Landoni, N. Colombo, A. Maggioni, 2003, International Journal of Gynecologic Cancer.

Corrections to "Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

F. Landoni, N. Colombo, C. Marth, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset

S. Rizzo, N. Colombo, G. Scambia, 2022, Cancers.

Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes.

N. Colombo, M. Achilarre, A. Garbi, 2016, Journal of minimally invasive gynecology.

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.

Jae-Weon Kim, B. Monk, I. Vergote, 2015, Gynecologic oncology.

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.

N. Colombo, S. Mammoliti, B. Tholander, 2012, Gynecologic oncology.

Platinum-Based Neoadjuvant Chemotherapy Followed by Radical Surgery for Cervical Carcinoma International Federation of Gynecology and Obstetrics Stage IB2-IIB

F. Landoni, N. Colombo, A. Maggioni, 2013, International Journal of Gynecologic Cancer.

Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.

A. Gadducci, E. Sartori, F. Landoni, 2005, Gynecologic Oncology.

Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient

N. Colombo, 2014, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

Controversies in chemotherapy — what is standard treatment?

N. Colombo, 2003 .

Role of chemotherapy in relapsed ovarian cancer.

N. Colombo, A. Maggioni, M. Sideri, 1999, Critical reviews in oncology/hematology.

The Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer

M. Buyse, N. Colombo, S. Pecorelli, 1996 .

Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study

S. Pignata, V. Canzonieri, G. Scognamiglio, 2021, Cancers.

Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.

N. Colombo, C. Jommi, P. Armeni, 2020 .

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

D. Provencher, M. Birrer, I. Vergote, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

V. Torri, G. Jayson, I. Floriani, 2003, Lancet.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

F. D. De Braud, G. Curigliano, C. Sessa, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression

M. Gobbi, N. Colombo, M. Miglino, 2012, Leukemia & lymphoma.

Safety and dose modification for patients receiving niraparib

J. Ledermann, J. Berek, I. Vergote, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

F. Landoni, N. Colombo, C. Marth, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.

F. Landoni, N. Colombo, M. Maruccio, 2017, Anticancer research.

Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia

M. Gobbi, A. Ibatici, N. Colombo, 2006, Leukemia & lymphoma.

Platinum, Anthracycline, and Alkylating Agent-Based Chemotherapy for Ovarian Carcinosarcoma

N. Colombo, R. Fruscio, L. Minig, 2009, International Journal of Gynecologic Cancer.

Letter to the Editor

V. Torri, N. Colombo, A. Swart, 2004, International Journal of Gynecologic Cancer.

Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.

M. Buyse, M. Parmar, V. Torri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?

F. Malavasi, N. Colombo, C. Mangioni, 2004, Gynecologic oncology.

Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series

F. Landoni, N. Colombo, P. Harter, 2019, International Journal of Gynecological Cancer.

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?

I. Ray-Coquard, R. Coleman, N. Colombo, 2021, Cancers.

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

D. Katsaros, A. Gadducci, A. Lissoni, 2021, International Journal of Gynecological Cancer.

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

A. Reuss, I. Vergote, J. Sehouli, 2019, Gynecologic oncology.

Feasibility of Transabdominal Cardiophrenic Lymphnode Dissection in Advanced Ovarian Cancer: Initial Experience at a Tertiary Center

S. Rizzo, F. Landoni, N. Colombo, 2017, International Journal of Gynecologic Cancer.

TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO‐OVAR OP7).

A. Reuss, F. Guyon, J. Sehouli, 2017 .

Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit.

S. Rizzo, F. Landoni, N. Colombo, 2017, Gynecologic oncology.

Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.

H. Gabra, J. Sehouli, N. Colombo, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology: European Society of Gynecological Oncology (ESGO) Statement

R. Kimmig, A. Lopes, P. Zola, 2011, International Journal of Gynecologic Cancer.

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

A. Lissoni, G. Cavaletti, N. Colombo, 2003, Neurology.

Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study

L. Cavanna, P. Zola, M. D’Incalci, 2021, Journal of Ovarian Research.

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).

B. Monk, I. Vergote, S. Pignata, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Work Place Educational Climate in Gynecological Oncology Fellowships Across Europe: The Impact of Accreditation

K. Boor, N. Colombo, R. Verheijen, 2015, International Journal of Gynecologic Cancer.

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

A. Marchetti, F. Buttitta, M. Fassan, 2022, ESMO open.

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.

A. Oza, M. Friedlander, N. Colombo, 2022, Gynecologic oncology.

Effects of granulocyte‐monocyte colony‐stimulating factor (GM‐CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer‐associated macrophages

P. Allavena, A. Mantovani, S. Bernasconi, 1995, International journal of cancer.

Overexpression of p185 is not related to erbB2 amplification in ovarian cancer.

M. Campiglio, S. Ménard, N. Colombo, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

First-Line Therapy in Ovarian Cancer Trials

H. Kitchener, J. McAlpine, L. Rubinstein, 2011, International Journal of Gynecologic Cancer.

Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan.

F. Landoni, N. Colombo, A. Maggioni, 2009, Gynecologic oncology.

In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma

P. Allavena, A. Mantovani, S. Bernasconi, 2005, Cancer Immunology, Immunotherapy.

Human ovarian tumors in primary culture: Growth, characterization and initial evaluation of the response to cis platinum treatment in vitro

M. Broggini, M. D’Incalci, E. Erba, 1988, International journal of cancer.

Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice.

G. Franceschini, C. Sirtori, G. Chiesa, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial

B. Monk, A. Oza, J. Ledermann, 2020 .

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

F. Marmé, I. Vergote, S. Pignata, 2019, The New England journal of medicine.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

I. Ray-Coquard, N. Colombo, J. Prat, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Sessa, N. Colombo, A. Garbi, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories

A. Marchetti, F. Buttitta, P. Radice, 2019, Diagnostics.

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

K. Yonemori, S. Pignata, I. Ray-Coquard, 2022, The New England journal of medicine.

Goserelin with chemotherapy to preserve ovarian function in premenopausal women with early breast cancer : menstruation and pregnancy outcomes

I. Floriani, N. Colombo, A. Garbi, 2012 .

Intraperitoneal administration of interferon β in ovarian cancer patients

A. Mantovani, S. Landolfo, F. Colotta, 1985 .

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale

A. Caraceni, A. Lissoni, G. Cavaletti, 2007, Journal of the peripheral nervous system : JPNS.

In vitro cytotoxicity of VP-16213 on human ovarian cancer.

F. Landoni, M. D’Incalci, E. Erba, 1984 .

Ovarian Surface Epithelium The Differential Role of L 1 in Ovarian Carcinoma and Normal

A. Godwin, P. Nuciforo, M. Herlyn, 2008 .

Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

N. Colombo, 2013, Future oncology.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers

E. Scarpi, F. Landoni, V. Conteduca, 2022, Frontiers in Oncology.

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.

P. Fasching, F. Marmé, I. Vergote, 2022, European journal of cancer.

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.

I. Vergote, Jung-Min Lee, N. Colombo, 2022, Gynecologic oncology.

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

E. Kohn, V. Gebski, A. Reuss, 2022, The Lancet. Oncology.

Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.

A. Isacchi, E. Casale, E. Felder, 2014, Bioorganic & medicinal chemistry.

Chemo-conization in early cervical cancer.

F. Landoni, N. Colombo, A. Maggioni, 2007, Gynecologic oncology.

The disposition of carboplatin in ovarian cancer patients

R. Gaver, N. Colombo, Michael D. Green, 2004, Cancer Chemotherapy and Pharmacology.

Multimodality therapy of early-stage (FIGO I-II) ovarian cancer: review of surgical management and postoperative adjuvant treatment

N. Colombo, A. Maggioni, L. Bocciolone, 1996, International Journal of Gynecologic Cancer.

Cisplatin‐lnduced peripheral neurotoxicity is dependent on total‐dose intensity and single‐dose intensity

G. Cavaletti, G. Tredici, N. Colombo, 1992, Cancer.

VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study

A. Oza, I. Ray-Coquard, D. Spriggs, 2007 .

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

N. Biglia, N. Colombo, F. Peccatori, 2015, Ecancermedicalscience.

A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer

D. Matei, M. Einstein, C. Sessa, 2007 .

Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

D. Katsaros, A. Gadducci, A. Lissoni, 2021, International Journal of Gynecological Cancer.

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

A. Oza, J. Ledermann, E. Swisher, 2021, Cancer medicine.

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

A. Oza, J. Ledermann, D. Cella, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2021, The Lancet. Oncology.

The forefront of ovarian cancer therapy: update on PARP inhibitors.

S. Pignata, I. Ray-Coquard, R. Coleman, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

High‐dose epirubicin in patients with advanced or recurrent uterine sarcoma

F. Landoni, A. Lissoni, N. Colombo, 1997 .

Fertility-Sparing Options in Young Women with Cervical Cancer

F. Landoni, N. Colombo, F. Peccatori, 2016, Current Treatment Options in Oncology.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018 .

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.

A. Oza, J. Ledermann, E. Swisher, 2020, The Lancet. Oncology.

Implementing clinical practice guidelines: time to assess it

V. Torri, G. Curigliano, C. Sessa, 2020, ESMO Open.

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

M. Parmar, V. Torri, I. Vergote, 2003, Journal of the National Cancer Institute.

Erratum: The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial (Lancet (2003) 361 (2099-106))

M. Parmar, V. Torri, H. Adams, 2003 .

Different Platinum Schedules in the Treatment of Epithelial Ovarian Cancer

F. Landoni, N. Colombo, C. Mangioni, 1988 .

Stereotactic Body Radiotherapy For Oligometastatic Ovarian Cancer: A Step Towards A Drug Holiday

S. Gandini, N. Colombo, S. Volpe, 2018 .

Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: single institution experience.

D. Radice, F. Landoni, N. Colombo, 2012, Gynecologic oncology.

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.

D. Berton, I. Vergote, S. Pignata, 2020 .

Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer

I. Floriani, N. Colombo, A. Garbi, 2016, British Journal of Cancer.

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

A. Oza, M. Birrer, I. Vergote, 2018, Future oncology.

Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients

A. Rappa, N. Colombo, F. Multinu, 2022, Cancers.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

I. Vergote, I. McNeish, S. Pignata, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

S. Pignata, C. Sessa, I. Ray-Coquard, 2018 .

Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.

P. Allavena, A. Mantovani, A. Lissoni, 1990, Cancer research.

Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.

S. Gandini, N. Colombo, L. Paleari, 2017, Gynecologic oncology.

Intraperitoneal administration of interferon beta in ovarian cancer patients.

A. Mantovani, S. Landolfo, F. Colotta, 1985, Cancer.

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Jae-Weon Kim, N. Colombo, G. Scambia, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intervention debulking surgery (IDS) does increase survival in advanced epithelial ovarian cancer (OC); an EORTC gynecological cancer cooperative group (GCCG) study

M. Buyse, N. Colombo, S. Pecorelli, 1993 .

European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015

A. Reuss, J. Ledermann, R. Glasspool, 2015, International Journal of Gynecologic Cancer.

Ovarian Sex Cord-Stromal Tumors

N. Colombo, G. Parma, 2004 .

Surgical Management of Malignant Ovarian Germ‐Cell Tumors: 10 Years' Experience of 129 Patients

F. Landoni, N. Colombo, C. Mangioni, 1995, Obstetrics and gynecology.

Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary.

E. Sartori, F. Landoni, C. Sessa, 1986, Obstetrics and gynecology.

Detection of Sentinel Nodes by Lymphoscintigraphy and Gamma Probe Guided Surgery in Vulvar Neoplasia

N. Colombo, A. Maggioni, C. Mangioni, 2000, Tumori.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

I. Ray-Coquard, N. Colombo, J. Prat, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.

H. Mackay, A. Oza, H. Hirte, 2012 .

Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.

M. Gobbi, N. Colombo, M. Miglino, 2013, Leukemia research.

Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab

A. Gadducci, S. Pignata, V. Canzonieri, 2022, Diagnostics.

Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients

M. Gobbi, N. Colombo, M. Miglino, 2020, Leukemia & lymphoma.

Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes

P. Pelicci, N. Colombo, F. Bertolini, 2022, International journal of cancer.

Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.

M. Gobbi, N. Colombo, M. Miglino, 2006, Journal of experimental & clinical cancer research : CR.

When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.

N. Colombo, 2017, Future oncology.

Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge

N. Colombo, G. Ferrandina, C. Marth, 2016, Expert review of anticancer therapy.

Building clinical trials around patients: Evaluation and comparison of decentralized and conventional site models in patients with low back pain

N. Colombo, Pernilla Adolfsson, V. Arnera, 2018, Contemporary clinical trials communications.

A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.

M. Scorsetti, S. Pignata, V. Valentini, 2019, The oncologist.

Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial

F. Marmé, A. Gadducci, J. Rau, 2016, International Journal of Gynecologic Cancer.

Defective natural killer activity within human ovarian tumors: low numbers of morphologically defined effectors present in situ.

P. Allavena, A. Mantovani, A. Villa, 1983, Journal of the National Cancer Institute.

Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826

A. Okamoto, M. Yunokawa, K. Yonemori, 2022, Cancer science.

Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology About the Conservative Management of Ovarian Malignant Tumors

A. Schneider, N. Colombo, P. Morice, 2011, International Journal of Gynecologic Cancer.

A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer

A. Mariani, N. Colombo, F. Multinu, 2022, International Journal of Gynecological Cancer.

Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.

A. Ibatici, N. Colombo, T. Lamparelli, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD‐driven salvage approach

M. Gobbi, N. Colombo, M. Miglino, 2019, British journal of haematology.

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information

M. Gobbi, N. Colombo, M. Miglino, 2019, British journal of haematology.

Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia

M. Gobbi, A. Ibatici, N. Colombo, 2017, Haematologica.

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors

M. Galsky, K. Yonemori, C. Chappey, 2022, JAMA oncology.

Adult granulosa cell tumours of the ovary

N. Colombo, R. Portuesi, R. Mancari, 2014, Current opinion in oncology.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

E. Kohn, A. Okamoto, D. Provencher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

A. Oza, J. Ledermann, E. Swisher, 2020 .

Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment

J. Sehouli, N. Colombo, M. Gultekin, 2020, International Journal of Gynecological Cancer.

LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

A. Gadducci, J. Sehouli, N. Colombo, 2020 .

The role of restaging borderline ovarian tumors: single institution experience and review of the literature.

F. Landoni, N. Colombo, I. Zapardiel, 2010, Gynecologic oncology.

Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients

M. Piccart, N. Colombo, Michael D. Green, 2004, Cancer Chemotherapy and Pharmacology.

Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series.

I. Floriani, N. Colombo, A. Garbi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

A. Gadducci, S. Pignata, R. Danesi, 2022, Frontiers in Oncology.

ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit

V. Torri, J. Ledermann, N. Colombo, 2003, The Lancet.

Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.

F. Marmé, I. Vergote, I. Ray-Coquard, 2022, European journal of cancer.

Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

S. Pignata, N. Colombo, G. Scambia, 2021, International Journal of Gynecological Cancer.

8050 POSTER Cost-effectiveness of Trabectedin in Combination With Pegylated Liposomal Doxorubicin Hydrochloride for the Treatment of Women With Relapsed Platinum-sensitive Ovarian Cancer in the UK -Analysis Based on the Final Survival Data

M. Gore, I. Vergote, N. Colombo, 2011 .

Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues.

A. Leary, N. Colombo, P. Morice, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients.

H. Kajiyama, N. Colombo, P. Morice, 2015, Fertility and sterility.

Role of conservative surgery in ovarian cancer: the European experience

N. Colombo, A. Maggioni, F. Maggi, 2005, International Journal of Gynecologic Cancer.

Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy.

V. Torri, N. Colombo, A. Maggioni, 1994, Gynecologic oncology.

Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.

M. Gobbi, N. Colombo, M. Miglino, 2009, Oncology reports.

Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages.

A. Mantovani, N. Colombo, G. Peri, 1982, Clinical and experimental immunology.

Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers

P. Casali, C. Morosi, N. Colombo, 2020, Clinical sarcoma research.

Anti‐tumor and immunomodulatory activity of intraperitoneal IFN‐γ in ovarian carcinoma patients with minimal residual tumor after chemotherapy

P. Allavena, A. Mantovani, N. Colombo, 1992, International journal of cancer.

Fibroblastic Malignant Peripheral Nerve Sheath Tumour of the Uterine Cervix: Report of a Case and Literature Review With Emphasis on Possible Differential Diagnosis.

F. Landoni, N. Colombo, G. Aletti, 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

M. Dimopoulos, D. Bae, P. Schwartz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to M.L. Friedlander et al.

N. Colombo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update

N. Colombo, T. Lamparelli, A. Bacigalupo, 2015, Bone Marrow Transplantation.

Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients

S. Pignata, L. Portella, G. Scognamiglio, 2022, Cancers.

Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers).

C. Sessa, N. Colombo, D. Querleu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Matrix Gla Protein acts as a driver of stemness and tumor initiation in ovarian cancer

J. Olsen, U. Cavallaro, G. Bertalot, 2022, bioRxiv.

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells’ vulnerability to DNA-damaging agents

M. Gobbi, A. Neri, S. Bruzzone, 2017, Haematologica.

Myeloid neoplasms post PARP inhibitors for ovarian cancer

N. Colombo, I. Palaia, Giuseppe Caruso, 2023, International Journal of Gynecological Cancer.

1,3,4-Oxadiazole formation as traceless release in solid phase organic synthesis

E. Felder, N. Colombo, M. Pulici, 2006 .

Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.

A. Isacchi, A. Montagnoli, N. Colombo, 2009, Journal of medicinal chemistry.

ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease

J. Ledermann, I. Vergote, I. McNeish, 2019 .

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

D. Timmerman, J. Ledermann, R. Glasspool, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling

V. Berezin, E. Bock, U. Cavallaro, 2011, EMBO molecular medicine.

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.

A. Oza, M. Gore, H. Hirte, 2018, Gynecologic oncology.

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.

D. Provencher, J. Ledermann, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Pure Ovarian Immature Teratoma, a Unique and Curable Disease: 10 Years' Experience of 32 Prospectively Treated Patients

N. Colombo, C. Mangioni, F. Peccatori, 1994, Obstetrics and gynecology.

The Role of Surgery in Gestational Trophoblastic Disease

C. Belloni, N. Colombo, C. Mangioni, 1983, Tumori.

Ovarian Sex Cord Tumors

N. Colombo, M. Achilarre, A. Garbi, 2017 .

Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients

N. Colombo, S. Filippi, A. Loppini, 2021, International Journal of Gynecological Cancer.

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

F Landoni, C Marini, F. Landoni, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma.

M. Parmar, V. Torri, I. Vergote, 2003, Journal of the National Cancer Institute.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C Marini, C. Sessa, N. Colombo, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study.

V. Torri, D. Katsaros, E. Sartori, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Gabe S. Sonke, Anne Floquet, Kathleen Moore, 2018, The New England journal of medicine.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

N. Colombo, P. Benedetti Panici, F. Tomao, 2020, Cancer management and research.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

H. Mackay, A. Oza, J. Barrett, 2015, The Lancet. Oncology.

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma

M. Gobbi, N. Colombo, L. Canepa, 2015, BioMed research international.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

D. Alberts, R. Burger, E. Trimble, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling

U. Cavallaro, P. Ubezio, A. Villa, 2021, Journal of experimental & clinical cancer research : CR.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Sessa, N. Colombo, C. Fotopoulou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemotherapy in cervical cancer: an update

N. Colombo, R. Portuesi, G. Parma, 2015, Expert review of anticancer therapy.

The Systemic Treatment of Recurrent Ovarian Cancer revisited.

J. Ledermann, N. Colombo, F. Joly, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer

J. Ledermann, C. Sessa, F. Amant, 2015, International Journal of Gynecologic Cancer.

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

D. Matei, M. Einstein, F. Haluska, 2013, British Journal of Cancer.

ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.

J. Ledermann, C. Sessa, F. Amant, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.

J. Ledermann, C. Sessa, F. Amant, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy

B. Bonanni, G. Viale, A. Rappa, 2019, Cancers.

A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance.

I. Vergote, S. Pignata, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Val Gebski, Philipp Harter, Tomasz Huzarski, 2017, The Lancet. Oncology.

Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum‐free interval: Myth or reality?

M. D’Incalci, N. Colombo, F. Peccatori, 2017, Cancer.

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.

A. Oza, J. Ledermann, E. Swisher, 2022, Gynecologic oncology.

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

D. Berton, I. Vergote, S. Pignata, 2021, Gynecologic Oncology.

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial

D. Berton, I. Vergote, S. Pignata, 2023, JCO precision oncology.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

V. Torri, M. Parmar, J. Ledermann, 2003, The Lancet.

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.

C. V. van Asperen, I. Vergote, D. Stoppa-Lyonnet, 2016, European journal of cancer.

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.

A. Ballestrero, F. Patrone, E. Moran, 2010, Leukemia research.

ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

S. Marnitz, J. Ledermann, I. Vergote, 2021, Virchows Archiv.

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

Cyrus Chargari, S. Marnitz, J. Ledermann, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Cyrus Chargari, S. Marnitz, J. Ledermann, 2020, International Journal of Gynecological Cancer.

Tumor‐derived chemotactic factor(S) from human ovarian carcinoma: Evidence for a role in the regulation of macrophage content of neoplastic tissues

A. Mantovani, P. Ghezzi, M. Salmona, 1985, International journal of cancer.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup

A. Jimeno, D. Katsaros, I. Vergote, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

D. Katsaros, A. Gadducci, C. Sessa, 2012, International Journal of Gynecologic Cancer.

Methotrexate with Citrovorum Factor in Low-Risk Gestational Trophoblastic Tumor

N. Colombo, G. Mangili, Giorgia Mangili, 1987, Tumori.

Management of ovarian stromal cell tumors.

N. Colombo, V. Zanagnolo, A. Insinga, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endometrial carcinosarcoma

B. Monk, A. Mariani, S. Pignata, 2022, International Journal of Gynecological Cancer.

Clinical presentation, diagnosis and management of therapy‐related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly‐ADP‐ribose polymerase inhibitors: A single‐center experience

N. Colombo, F. Bertolini, G. Gregato, 2020, International journal of cancer.

Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.

Jae-Weon Kim, V. Gebski, A. Oza, 2020, European journal of cancer.

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis

V. Torri, A. Lissoni, N. Colombo, 2008, British Journal of Cancer.

Special issues in fertility preservation for gynecologic malignancies.

N. Colombo, V. Zanagnolo, F. Peccatori, 2016, Critical reviews in oncology/hematology.

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

I. Tannock, M. Parmar, R. Souhami, 2002, The Lancet.

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

J B Vermorken, K. Swenerton, E. Eisenhauer, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

M. Buyse, N. Colombo, S. Pecorelli, 1995, The New England journal of medicine.

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

I. Vergote, J. Rau, A. Cardona, 2019, International Journal of Gynecological Cancer.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors

D. Provencher, J. Ledermann, R. Glasspool, 2014, International Journal of Gynecologic Cancer.

DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response

P. Allavena, A. Mantovani, N. Colombo, 2004, Cancer Immunology, Immunotherapy.

External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma

E. Keung, C. Raut, M. Nucci, 2013, Cancer.

Treatment Options for Pregnant Women With Ovarian Tumors

N. Biglia, N. Colombo, H. Azim, 2014, International Journal of Gynecologic Cancer.

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).

I. Vergote, I. Ray-Coquard, I. Benjamin, 2021, Gynecologic oncology.

Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

A. Oza, I. Bondarenko, N. Colombo, 2021 .

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.

B. Monk, A. Oza, H. Hirte, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.

A. Gadducci, S. Pignata, C. Sessa, 2021, The Lancet. Oncology.

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

B. Monk, A. Oza, I. Vergote, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma

A. Oza, N. Colombo, Joyce F. Liu, 2021, International Journal of Gynecological Cancer.

Uterine serous carcinoma.

B. Monk, D. Provencher, A. Mariani, 2021, Gynecologic oncology.

Aggressive angiomyxoma of the vulva.

N. Colombo, N. Surico, D. Surico, 2004, Gynecologic oncology.

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.

B. Monk, N. Colombo, K. Hasegawa, 2021, The New England journal of medicine.

Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).

A. Gadducci, R. Corvò, A. D. Dei Tos, 2020, European journal of cancer.

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.

B. Monk, A. Oza, J. Ledermann, 2021, The Lancet. Oncology.

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer

V. Torri, A. Lissoni, M. D’Incalci, 2019, British Journal of Cancer.

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

I. Ray-Coquard, N. Colombo, J. López-Guerrero, 2014, Cancer treatment reviews.

Intravenous aflibercept in patients with platinum‐resistant, advanced ovarian cancer: Results of a randomized, double‐blind, phase 2, parallel‐arm study

D. Matei, A. Oza, Z. Shun, 2014, Cancer.

CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells

U. Cavallaro, S. Confalonieri, G. Bertalot, 2018, Stem cell reports.

III.4 Tamoxifen and the Uterus: Potential Uterine Risks of Anti-oestrogens. The Approach of the European Institute of Oncology

Alberto Costa, N. Colombo, A. Maggioni, 1998 .

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

A. Oza, Byoung-Gie Kim, M. Friedlander, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

A. Oza, E. Parkhomenko, M. Friedlander, 2021, The Lancet. Oncology.

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock

Thomas E. Bartlett, M. Widschwendter, N. Harbeck, 2022, Genome biology.

Reduction of Postoperative Complication Rate with the Use of Early Oral Feeding in Gynecologic Oncologic Patients Undergoing a Major Surgery: A Randomized Controlled Trial

F. Landoni, N. Colombo, A. Maggioni, 2009, Annals of Surgical Oncology.

Splenectomy as Part of Primary Cytoreductive Surgery for Advanced Ovarian Cancer: A Retrospective Cohort Study

F. Landoni, N. Colombo, I. Zapardiel, 2012, International Journal of Gynecologic Cancer.

Early Oral Versus “Traditional” Postoperative Feeding in Gynecologic Oncology Patients Undergoing Intestinal Resection: a Randomized Controlled Trial

F. Landoni, N. Colombo, A. Maggioni, 2009, Annals of Surgical Oncology.

Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.

A. Bardelli, A. Goldhirsch, C. Criscitiello, 2014, Cancer treatment reviews.

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

M. Gore, Y. Park, C. Sessa, 2013, Medical Oncology.

Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center

M. Dieci, N. Colombo, F. Peccatori, 2020, Frontiers in Oncology.

WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia

M. Gobbi, N. Colombo, M. Miglino, 2011, Leukemia & lymphoma.

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

S. Pignata, U. Matulonis, Jiuzhou Wang, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies

J. Ledermann, C. Sessa, N. Colombo, 2020, ESMO Open.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

B. Monk, B. van Calster, R. Wenham, 2019, The Lancet. Oncology.

Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.

Gloria S. Huang, S. Pignata, J. Fiorica, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups

S. Pignata, N. Colombo, M. Cascella, 2021, Journal of gynecologic oncology.

Pre‐transplant minimal residual disease assessment and transplant‐related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation

M. Gobbi, N. Colombo, E. Angelucci, 2021, European journal of haematology.

Peripheral neurotoxicity of taxol in patients previously treated with cisplatin

G. Cavaletti, G. Tredici, N. Colombo, 1995 .

Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M. Castiglione, N. Colombo, M. Peiretti, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.

K. Rhodes, I. Vergote, I. Ray-Coquard, 2021, European journal of cancer.

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

K. King, Chun-Fang Xu, T. Johnson, 2016, Gynecologic oncology.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

M. Nicoloso, S. Pignata, G. de Matteis, 2023, The Lancet. Oncology.

A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer

K. Yonemori, S. Pignata, I. Ray-Coquard, 2021, Gynecologic Oncology.

2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma

A. Oza, J. Ledermann, R. Coleman, 2022, Ovarian cancer.

Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)

N. Colombo, G. Scambia, E. Lowe, 2022, Gynecologic Oncology.

Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)

S. Pignata, U. Matulonis, Jiuzhou Wang, 2022, Gynecologic Oncology.

AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.

A. Reuss, N. Colombo, D. Cibula, 2022, Journal of Clinical Oncology.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

B. Monk, H. Mackay, D. Miller, 2021, Annals of Oncology.

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.

P. Tagliaferri, S. Pignata, C. Sonetto, 2019, Gynecologic oncology.

Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer.

G. Cavaletti, G. Tredici, N. Colombo, 1994, Anticancer research.

Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.

N. Colombo, Erlisa Bardhi, F. Tomao, 2019, Cancer treatment reviews.

A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma

V. Torri, F. Grosso, A. Santoro, 2018, British Journal of Cancer.

Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy

N. Colombo, M. Augugliaro, B. Jereczek-Fossa, 2020, International Journal of Gynecological Cancer.

B. Monk, N. Colombo, K. Hasegawa, 2023, The Lancet. Oncology.

The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership

J. Ledermann, R. Glasspool, I. Vergote, 2015, International Journal of Gynecologic Cancer.

Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1

A. Oza, M. Friedlander, Byoung-Gie Kim, 2021, Gynecologic Oncology.

Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

B. Monk, A. Tinker, A. Oza, 2021, Gynecologic Oncology.

External validation of a nomogram predicting overall survival (OS) of women with uterine leiomyosarcoma (ULMS).

E. Keung, C. Raut, M. Nucci, 2012 .

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

B. Monk, A. Oza, M. Birrer, 2019, Annals of Oncology.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study

C. Tournigand, A. Schneeweiss, C. Bokemeyer, 2014, Medical Oncology.

Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer

H. Earl, M. Gore, C. Sessa, 2001 .

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

F. Landoni, N. Colombo, C. Marth, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

B. Monk, A. Oza, I. Vergote, 2021 .

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

B. Monk, A. Oza, R. Wenham, 2017, European journal of cancer.

High precision radiotherapy including intensity-modulated radiation therapy and pulsed-dose-rate brachytherapy for cervical cancer: a retrospective monoinstitutional study

S. Rizzo, R. Orecchia, N. Colombo, 2019, Journal of contemporary brachytherapy.

The WID‐EC test for the detection and risk prediction of endometrial cancer

T. Mould, M. Widschwendter, J. Dillner, 2022, International journal of cancer.

MRI- and Histologic-Molecular-Based Radio-Genomics Nomogram for Preoperative Assessment of Risk Classes in Endometrial Cancer

C. Catalano, N. Colombo, E. Faiella, 2022, Cancers.

International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.

M. Parmar, V. Torri, A. Lissoni, 2003, Journal of the National Cancer Institute.

Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.

F. Landoni, A. Lissoni, N. Colombo, 2020, Gynecologic oncology.

Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.

V. Torri, I. Floriani, N. Colombo, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis

A. Rappa, N. Colombo, I. Betella, 2019, Journal of Clinical Pathology.

Corrections to "Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

F. Landoni, N. Colombo, C. Marth, 2018 .

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

C. Schade-Brittinger, F. Marmé, I. Vergote, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are monoclonal antibodies a safe treatment for cancer during pregnancy?

N. Colombo, H. Azim, F. Peccatori, 2013, Immunotherapy.

Stereotactic Body Radiotherapy For Oligometastatic Ovarian Cancer: A Step Towards A Drug Holiday

R. Orecchia, S. Gandini, N. Colombo, 2018 .

The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples

A. Ryan, M. Widschwendter, J. Dillner, 2022, Nature Communications.

Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)

James X. Sun, A. Oza, J. Ledermann, 2018, Metabolic Changes in Ovarian Cancer.

Effect ofastreptococcal preparation (OK432) onnatural killer activity oftumour-associated lymphoid cells inhuman ovarian carcinoma andonlysis offresh ovarian tumourcells

A. Mantovani, F. Colotta, N. Colombo, 1983 .

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Castiglione, C. Sessa, N. Colombo, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.

A. Ryan, M. Widschwendter, M. Zikan, 2019, The Lancet. Oncology.

NATURAL KILLER ACTIVITY IN HUMAN OVARIAN TUMORS

P. Allavena, A. Mantovani, N. Colombo, 1982 .

Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells.

A. Mantovani, F. Colotta, N. Colombo, 1983, British Journal of Cancer.

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk‐oriented consolidation: A critical review of a 10‐year, single‐center experience in younger, non M3 AML patients

M. Gobbi, N. Colombo, A. Bacigalupo, 2016, American journal of hematology.

Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study

N. Colombo, L. Paleari, A. Decensi, 2020, International journal of molecular sciences.

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden

M. Gobbi, R. Fanin, N. Colombo, 2020, Cancers.

Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.

S. Pignata, U. Matulonis, Jiuzhou Wang, 2022, Journal of Clinical Oncology.

Maintenance Therapy for First-Line Treatment of Ovarian Cancer: Is This the Strategy for the Future?

R. Burger, N. Colombo, L. Minig, 2014 .

Feasibility of robotic radical hysterectomy after neoadjuvant chemotherapy in women with locally advanced cervical cancer.

N. Colombo, A. Maggioni, V. Zanagnolo, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions

N. Colombo, F. Multinu, G. Aletti, 2023, International Journal of Gynecological Cancer.

Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.

D. Radice, F. Landoni, N. Colombo, 2010, Gynecologic oncology.

Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy

P. Summers, S. Rizzo, F. Landoni, 2011, La radiologia medica.

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

A. Marchetti, P. Radice, P. Tassone, 2016, Future oncology.

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.

J. Ledermann, N. Colombo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial

N. Colombo, G. Scambia, D. Cibula, 2019, International Journal of Gynecological Cancer.

Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

N. Colombo, G. Scambia, D. Cibula, 2019, Journal of Clinical Oncology.

LBA40_PRARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)

James X. Sun, A. Oza, J. Ledermann, 2017 .

Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study

A. Oza, J. Ledermann, M. Friedlander, 2017 .

Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence

J. Sehouli, N. Colombo, B. Ataseven, 2023, International Journal of Gynecological Cancer.

Cisplatin (P), vinblastine (V), and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa cell tumor of the ovary (GCTO): An eortc gynecology cancer cooperative group study

R. Willemze, N. Colombo, J. Vermorken, 1989 .

Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.

N. Colombo, A. Maggioni, V. Zanagnolo, 2020, Gynecologic oncology.

An active chemotherapy regimen for advanced ovarian sex cord-stromal tumors.

N. Colombo, D. Franchi, G. Parma, 1999, Gynecologic oncology.

Robotic surgery: changing the surgical approach for endometrial cancer in a referral cancer center.

F. Landoni, N. Colombo, A. Maggioni, 2009, Journal of minimally invasive gynecology.

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future

N. Colombo, P. Scollo, D. Lorusso, 2017, International Journal of Gynecologic Cancer.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

A. Reuss, I. Vergote, S. Pignata, 2016, The Lancet. Oncology.

Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.

D. Provencher, J. Ledermann, T. Park-Simon, 2017 .

Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer.

N. Colombo, A. Maneo, C. Mangioni, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Low-dose oral etoposide in epithelial cancer of the ovary.

F. Cavalli, M. Zucchetti, C. Sessa, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound.

C. Di Mario, G. Franceschini, C. Sirtori, 2000, Atherosclerosis.

How to Address Sexual Problems in Female Cancer Patients.

F. Landoni, N. Colombo, D. Dizon, 2017, Oncology.

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer

A. Oza, A. Gadducci, N. Colombo, 2016, International Journal of Gynecologic Cancer.

Critical Review of Neoadjuvant Chemotherapy Followed by Surgery for Locally Advanced Cervical Cancer

N. Colombo, M. Peiretti, 2010, International Journal of Gynecologic Cancer.

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

M. Gobbi, N. Colombo, A. Nencioni, 2015 .

Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3

A. Oza, J. Ledermann, E. Swisher, 2020 .

Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial.

P. Tagliaferri, S. Pignata, N. Colombo, 2015 .

Teniposide in refractory ovarian cancer: a phase II study.

F. Landoni, C. Sessa, M. D’Incalci, 1984, Cancer treatment reports.

S. Pignata, I. Ray-Coquard, N. Colombo, 2021, Journal of Clinical Oncology.

Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.

I. Soubeyran, I. Vergote, N. Sevenet, 2020, Journal of the National Cancer Institute.

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.

F. Patrone, M. Gobbi, N. Colombo, 2013, Current Cancer Drug Targets.

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

A. Oza, I. Ray-Coquard, Byoung-Gie Kim, 2013, Gynecologic oncology.

Robotic approach for cervical cancer: comparison with laparotomy: a case control study.

F. Landoni, N. Colombo, A. Maggioni, 2009, Gynecologic oncology.

Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma

C. Sessa, A. Fasolo, L. Gianni, 2008 .

Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells

M. Gariboldi, J. Reid, M. Pierotti, 2007, Oncogene.

A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer

L. Baglietto, R. Montironi, G. Viale, 2006, Cancer Epidemiology Biomarkers & Prevention.

Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.

M. Nooij, M. Namer, I. Vergote, 2001, Gynecologic oncology.

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

M. Gobbi, N. Colombo, M. Miglino, 2018, Blood.

A blastic plasmacytoid dendritic cell neoplasm‐like phenotype identifies a subgroup of npm1‐mutated acute myeloid leukemia patients with worse prognosis

M. Gobbi, N. Colombo, M. Miglino, 2018, American journal of hematology.

A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.

M. Gobbi, N. Colombo, M. Miglino, 2019, Leukemia research.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

A. Marchetti, F. Buttitta, P. Radice, 2019, Critical reviews in oncology/hematology.

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

A. Oza, J. Ledermann, E. Swisher, 2020, Gynecologic Oncology.

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future.

N. Colombo, P. Scollo, D. Lorusso, 2017, International Journal of Gynecological Cancer.

S. Pignata, I. Ray-Coquard, N. Colombo, 2023, European Journal of Cancer.

Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer.

A. Lissoni, N. Colombo, A. Garbi, 2011, Journal of the National Cancer Institute.

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Jae-Weon Kim, A. Oza, M. Friedlander, 2021, Gynecologic oncology.

LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

R. Glasspool, B. Asselain, I. Ray-Coquard, 2021, Annals of Oncology.

Safety and dose modification for patients receiving niraparib.

J. Berek, I. Vergote, S. Ellard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly cisplatin ± glutathione in relapsed ovarian carcinoma

G. Cavaletti, N. Colombo, C. Mangioni, 1994, International Journal of Gynecologic Cancer.

Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.

E. De Ponti, A. Gadducci, A. Lissoni, 2014, Gynecologic oncology.

KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

B. Monk, T. Fehm, N. Colombo, 2019, Journal of Clinical Oncology.

BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).

N. Colombo, M. Mirza, A. Oaknin, 2019, Journal of Clinical Oncology.

811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

A. Oza, M. Friedlander, C. Aghajanian, 2020 .

Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′-deoxyuridine

C. Russell, N. Colombo, F. Muggia, 2004, Cancer Chemotherapy and Pharmacology.

392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study

M. Friedlander, N. Colombo, G. Scambia, 2020 .

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

A. Reuss, A. Okamoto, S. Lheureux, 2019, Journal of Clinical Oncology.

Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation

M. Gobbi, N. Colombo, A. Bacigalupo, 2014 .

Role of Pelvic Exenteration in the Treatment of Persistent or Recurrent Gynecological Cancers

F. Landoni, N. Colombo, A. Aloisi, 2020, Austin Journal of Obstetrics and Gynecology.

Radiation Exposure of Ovarian Cancer Patients: Contribution of CT Examinations Performed on Different MDCT (16 and 64 Slices) Scanners and Image Quality Evaluation

D. Origgi, S. Rizzo, M. Bellomi, 2015, Medicine.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Sessa, N. Colombo, C. Fotopoulou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.

S. Marsoni, N. Colombo, C. Mangioni, 1991, Cancer treatment reviews.

The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111).

V. Torri, N. Colombo, A. Swart, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.

M. Scorsetti, S. Pignata, V. Valentini, 2020 .

Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer

K. Yonemori, S. Pignata, I. Ray-Coquard, 2022, Obstetrical & Gynecological Survey.

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay

A. Rappa, N. Colombo, I. Betella, 2022, Pathologica.

Corrections to "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

C. Sessa, N. Colombo, C. Fotopoulou, 2018 .

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

M. Tiemann, I. Vergote, Eva-Maria Willing, 2023, Cancers.

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

A. Oza, J. Ledermann, E. Swisher, 2021, International Journal of Gynecological Cancer.

PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.

I. Vergote, S. Pignata, I. Ray-Coquard, 2016 .

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

B. Monk, K. Yonemori, I. Ray-Coquard, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.

I. Floriani, S. Pignata, N. Colombo, 2017, Gynecologic oncology.

PLATINUM COMBINATION CHEMOTHERAPY VERSUS PLATINUM MONOTHERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A META-ANALYSIS OF RANDOMISED TRIALS USING INDIVIDUAL PATIENT DATA (IPD)

D. Alberts, M. Parmar, J. Ledermann, 2012 .

Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.

B. Monk, Chun-Fang Xu, T. Johnson, 2014 .

Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line

N. Colombo, 2018, Expert review of anticancer therapy.

Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial.

I. Ray-Coquard, N. Colombo, G. Scambia, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.

A. Gadducci, F. Landoni, A. Lissoni, 2023, Gynecologic oncology.

8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials

J. Sehouli, N. Colombo, A. Nieto, 2011 .

A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma

V. Torri, F. Grosso, A. Santoro, 2018, British Journal of Cancer.

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.

A. Oza, M. Friedlander, C. Aghajanian, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III

A. Reuss, R. Wenham, A. Okamoto, 2023, Journal of Clinical Oncology.

2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial

M. Tiemann, I. Vergote, Eva-Maria Willing, 2022, Pathology.

O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma

A. Oza, J. Ledermann, R. Coleman, 2022, Oral Abstracts (Regular and Late-Breaking Submission).

LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3

N. Colombo, G. Scambia, D. Cibula, 2022, Oral Abstracts (Regular and Late-Breaking Submission).

Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.

A. Oza, R. Glasspool, S. Pignata, 2022, Journal of Clinical Oncology.

ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status

A. Oza, R. Glasspool, S. Pignata, 2021, Gynecologic Oncology.

ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.

S. Pignata, R. Coleman, N. Colombo, 2020 .

Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

A. Reuss, I. Ray-Coquard, N. Colombo, 2019, International journal of cancer.

A phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens

D. Katsaros, A. Gadducci, C. Sessa, 2008 .

Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2019, Journal of Clinical Oncology.

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

A. Monnier, P. Fumoleau, N. Colombo, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.

N. Colombo, H. Hochster, F. Muggia, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

M. Kris, A. Horwich, C. Buske, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Castiglione, C. Sessa, N. Colombo, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Rosia: A Single-Arm Study in More Than 1000 Patients (PTS) Receiving Front-Line Bevacizumab (BEV) + Chemotherapy (CT) for Ovarian Cancer (OC)

A. Oza, N. Colombo, F. Selle, 2012 .

Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trial

C. Sessa, M. D’Incalci, N. Colombo, 2004, Cancer Chemotherapy and Pharmacology.

Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer.

A. Lissoni, C. Sessa, N. Colombo, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

A reassessment of the role of second-look laparotomy in advanced ovarian cancer.

N. Colombo, U. Beller, N. Colombo, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

327 Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2)

N. Colombo, 2003 .

ESGO statement on cervical cancer vaccination: August 2007

I. Jacobs, I. Vergote, N. Colombo, 2007, International Journal of Gynecologic Cancer.

Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock

Thomas E. Bartlett, M. Widschwendter, N. Harbeck, 2022, Genome Biology.

Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies

T. Ciuleanu, C. Sessa, N. Colombo, 2007 .

Cardio-oncology: a new medical issue

N. Colombo, A. Colombo, D. Cardinale, 2008, Ecancermedicalscience.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J. Ledermann, C. Sessa, N. Colombo, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.

V. Torri, S. Marsoni, N. Colombo, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

D. Katsaros, L. Cavanna, I. Meinhold-Heerlein, 2023, British Journal of Cancer.

The interplay between NCAM and FGFR signalling underlies ovarian cancer progression

U. Cavallaro, N. Colombo, 2011, Ecancermedicalscience.

Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations

C. Belloni, S. Marsoni, N. Colombo, 1986 .

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

A. Berkenblit, S. Pignata, Susana Banerjee, 2023, Journal of Clinical Oncology.

2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine

A. Oza, M. Birrer, U. Matulonis, 2022, Ovarian cancer.

O028/#376 Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the soraya study

S. Pignata, U. Matulonis, Jiuzhou Wang, 2022, Focused Plenary Abstracts.

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.

J. Ledermann, C. Sessa, F. Amant, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?

W. Cliby, N. Colombo, F. Multinu, 2023, International Journal of Gynecological Cancer.

Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.

A. Oza, R. Glasspool, S. Pignata, 2023, Gynecologic oncology.

Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician.

M. Piccart, D. V. Von Hoff, G. Clark, 1990, Journal of the National Cancer Institute.

740P Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study

A. Barnicle, N. Colombo, K. Lindemann, 2021, Annals of Oncology.

987TiPOReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer

R. Glasspool, F. Marmé, B. Asselain, 2017 .

Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum

C. Sessa, M. D’Incalci, N. Colombo, 2004, Cancer Chemotherapy and Pharmacology.

Optimization of Diarylthiazole B‐Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect

M. Modugno, A. Isacchi, E. Casale, 2015, ChemMedChem.

Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

A. Lissoni, G. Cavaletti, N. Colombo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.

S. Pignata, N. Colombo, D. Cibula, 2022, Journal of Clinical Oncology.

The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma

R. L. Coleman, A. Oza, J. Ledermann, 2019, Gynecologic Oncology.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

V. Gebski, A. Oza, J. Ledermann, 2017, The Lancet. Oncology.

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.

N. Colombo, S. Mammoliti, B. Tholander, 2012, Gynecologic Oncology.

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.

P. Neven, D. Lambrechts, I. Vergote, 2023, European journal of cancer.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

A. Reuss, I. Vergote, S. Pignata, 2016, The Lancet. Oncology.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

H. Mackay, A. Oza, M. Friedlander, 2015, The Lancet. Oncology.

Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.

D. Radice, F. Landoni, N. Colombo, 2010, Gynecologic oncology.

Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

A. Reuss, H. Mackay, A. Oza, 2010, International Journal of Gynecologic Cancer.

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

B. Monk, A. Oza, I. Vergote, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

M. Parmar, J. Ledermann, I. Vergote, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Gestational choriocarcinoma

I. Vergote, S. Pignata, N. Concin, 2023, International Journal of Gynecological Cancer.

DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment

M. Widschwendter, M. Zikan, N. Colombo, 2023, NPJ precision oncology.

M. Gobbi, N. Colombo, M. Miglino, 2012, Leukemia & lymphoma.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

I. Ray-Coquard, N. Colombo, J. Prat, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Imaging in gynecological disease (8): ultrasound characteristics of recurrent borderline ovarian tumors

D. Timmerman, L. Valentin, N. Colombo, 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Castiglione, C. Sessa, N. Colombo, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.

C. Sessa, M. D’Incalci, N. Colombo, 1982, Cancer treatment reports.

Splenectomy as Part of Primary Cytoreductive Surgery for Advanced Ovarian Cancer: A Retrospective Cohort Study

F. Landoni, N. Colombo, I. Zapardiel, 2012, International Journal of Gynecologic Cancer.

Diaphragmatic Surgery During Primary Cytoreduction for Advanced Ovarian Cancer: Peritoneal Stripping Versus Diaphragmatic Resection

F. Landoni, N. Colombo, I. Zapardiel, 2011, International Journal of Gynecologic Cancer.

A. Jimeno, D. Katsaros, I. Ray-Coquard, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer: New Data From the Randomized OVA-301 Study

N. Colombo, 2011, International Journal of Gynecologic Cancer.

Molecular Recognition of T:G Mismatched Base Pairs in DNA as Studied by Electrospray Ionization Mass Spectrometry

G. Aldini, G. Vistoli, R. D'Alessio, 2012, ChemMedChem.

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

M. Mouret-Reynier, N. Colombo, A. Floquet, 2021, Gynecologic oncology.

2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection

I. Vergote, S. Pignata, I. Treilleux, 2022, Ovarian cancer.

Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)

P. Neven, D. Lambrechts, I. Vergote, 2022, Gynecologic Oncology.

ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

B. Monk, A. Oza, R. Coleman, 2022, Journal of Clinical Oncology.

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994

D. Katsaros, I. Vergote, F. Landoni, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

B. Monk, M. Gumus, N. Colombo, 2023, Journal of Clinical Oncology.

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.

A. Oza, M. Friedlander, C. Aghajanian, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

A. Marchetti, P. Radice, P. Tassone, 2016, Future oncology.

A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer

R. Wenham, N. Colombo, E. Braicu, 2023, Gynecologic oncology.